Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Gains from Sales and Divestitures (2020 - 2022)

Historic Gains from Sales and Divestitures for Mirum Pharmaceuticals (MIRM) over the last 3 years, with Q4 2022 value amounting to $122464.0.

  • Mirum Pharmaceuticals' Gains from Sales and Divestitures fell 833.05% to $122464.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $122464.0, marking a year-over-year decrease of 833.05%. This contributed to the annual value of $122464.0 for FY2022, which is 833.05% down from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $122464.0 for Q4 2022, which was down 833.05% from $100194.0 recorded in Q3 2022.
  • Mirum Pharmaceuticals' 5-year Gains from Sales and Divestitures high stood at $133593.0 for Q4 2020, and its period low was $33396.0 during Q1 2021.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $83494.0 (2020), whereas its average is $82567.5.
  • Within the past 5 years, the most significant YoY rise in Mirum Pharmaceuticals' Gains from Sales and Divestitures was 0.6% (2022), while the steepest drop was 833.05% (2022).
  • Quarter analysis of 3 years shows Mirum Pharmaceuticals' Gains from Sales and Divestitures stood at $133593.0 in 2020, then changed by 0.0% to $133593.0 in 2021, then decreased by 8.33% to $122464.0 in 2022.
  • Its last three reported values are $122464.0 in Q4 2022, $100194.0 for Q3 2022, and $66796.0 during Q2 2022.